EE267 A Short-Term Cost-Effectiveness Analysis of Insulin Degludec/Insulin Aspart Versus Insulin Glargine U100 and Insulin Aspart in Patients with Type 2 Diabetes Inadequately Controlled on BASAL Insulin
Abstract
Authors
L Q. L Zhou N Zhou M Hu